1
|
Viviani L, Balks E, Beken S, Brady AM, Clayton R, Cliquet F, Desmayanti L, Fragoeiro S, Hamtak TJ, John D, Jungbaëck C, Kalaivani M, Kross I, Lang C, Ria Isriyanthi NM, Mallet L, Milne C, Rubbrecht M, Siklódi B, Singh B, Srinivas GB, Stickings P, Stirling C, Sundram P, Szabó M, Thomas A, van den Berg M, Walker A, Philippe C, Vandeputte J. 3Rs implementation in veterinary vaccine batch-release testing: Current state-of-the-art and future opportunities. A webinar and workshop report. Biologicals 2023; 83:101695. [PMID: 37516084 DOI: 10.1016/j.biologicals.2023.101695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Revised: 06/20/2023] [Accepted: 07/14/2023] [Indexed: 07/31/2023] Open
Abstract
Regulatory authorities require veterinary batch-release testing to confirm vaccine potency and safety, but these tests have traditionally relied on large numbers of laboratory animals. Advances in vaccine research and development offer increasing opportunities to replace in vivo testing, and some stakeholders have made significant progress in incorporating 3Rs elements in quality control strategies. A three-part event series entitled "3Rs Implementation in Veterinary Vaccine Batch-Release Testing: Current state-of-the-art and future opportunities" was jointly organized by the Animal-Free Safety Assessment Collaboration, HealthforAnimals, and the International Alliance of Biological Standardization. Two webinars and a workshop aimed to outline the state-of-the-art non-animal approaches for veterinary batch-release testing. The events included information on the state of the deletion of obsolete safety testing and the current initiatives implemented by European, North American, and Asian-Pacific stakeholders on 3Rs implementation and regulatory acceptance. The events contributed to a better understanding of the barriers to 3Rs implementation. Participants highlighted the need for open communication, continued collaboration between stakeholders, and international harmonization of regulatory requirements to help accelerate acceptance. Despite the challenges, the countries represented at this three-part event have shared their commitments to advancing the acceptance of alternative methods.
Collapse
Affiliation(s)
- Laura Viviani
- SciethiQ, under contract with Humane Society International, Basel, Switzerland.
| | - Elisabeth Balks
- Paul-Ehrlich-Institut, Langen, Germany; European Medicines Agency (EMA), Brussels, Belgium
| | - Sonja Beken
- European Medicines Agency (EMA), Brussels, Belgium; Belgian Federal Agency for Medicines and Health Products (FAMPH), Brussels, Belgium
| | - Anna-Maria Brady
- Subject Matter Expert at European and British Pharmacopoeia, London, United Kingdom
| | | | - Florence Cliquet
- Agence Nationale de Sécurité Sanitaire de l'alimentation, de l'environnement et du Travail (French Agency for Food, Environmental and Occupational Health & Safety), ANSES-Nancy, France
| | | | | | | | | | - Carmen Jungbaëck
- International Alliance for Biological Standardization Europe (IABS), Geneva, Switzerland
| | - M Kalaivani
- Indian Pharmacopoeia Commission, Ghaziabad, India
| | - Imke Kross
- MSD Animal Health, Boxmeer, the Netherlands
| | - Catherine Lang
- European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, Strasbourg, France
| | | | - Laurent Mallet
- European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, Strasbourg, France
| | - Catherine Milne
- European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, Strasbourg, France
| | | | | | | | | | - Paul Stickings
- Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK; National Institute for Biological Standards and Control (NIBSC), Potters Bar, Hertfordshire, UK
| | | | | | - Mária Szabó
- World Organization for Animal Health, Paris, France
| | - Anne Thomas
- Zoetis Belgium SA, Ottignies-Louvain-la-Neuve, Belgium
| | | | - Angela Walker
- US Department of Agriculture (USDA)- APHIS, Riverdale, MD, USA
| | | | - Joris Vandeputte
- International Alliance for Biological Standardization Europe (IABS), Geneva, Switzerland
| |
Collapse
|
2
|
Andriyanto A, Isriyanthi NMR, Sastra EL, Arif R, Mustika AA, Manalu W. Aktivitas Antipiretik Ekstrak Etanol Buah Belimbing Wuluh (Averrhoa bilimbi) pada Tikus Putih Jantan (ANTIPYRETIC ACTIVITY OF ETHANOL EXTRACT OF BELIMBING WULUH (AVERRHOA BILIMBI) IN MALE WHITE RAT). JVet 2018. [DOI: 10.19087/jveteriner.2017.18.4.597] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
The experiment was conducted to study the activity of ethanol extract of belimbing wuluh (EEBW) as antipyretic. Fever induction was done by using difteri pertusis tetanus (DPT) vaccine intramuscularly at a dose of 0.1 mL/100 g BW. Male white rat strain spraque dawley with range of weight by 200 to 300 g was used in this research.Fifteen experimental rats were used to explore the specific time of fever (time of early fever and time of peak fever) which were divided in 2 treatments, i.e. 10 experimental rats with DPT vaccine injection and 5 experimental rats without DPT vaccine injection as control.Fourty experimental rats were used to study effectivity of EEBW as antipyretic which were grouped with factorial randomized design with 4 x 2 and 5 replications. The first factor was various substance administered which consisted of aquadest (control), EEBW 0.88 g/kg BW, EEBW 1.75 g/kg BW, and aspirin 0.004 g/kg BW.The second factor was time of fever detection, i.e. time of early stage fever and time of peak fever. The variable was measured with rectal temperature of the experimental rats by using digital thermometer (correction factor 0.01oC) every 30 minutes. The data were analyzed with t-student dan general linear model (GLM). Increasing of rectal temperature of experimental rats with DPT injection began at 30 minutes post-DPT injection (time of early stage fever) and reached time of peak fever at 210 minutes post-DPT injection. Ethanol extract of belimbing wuluh at dose of 1.75 g/kg BW administered at early fever lowered rectal temperature of the experimental rats compared to the other groups. It was concluded that the administration of EEBW at dose of 1.75 g/kg BW was effective combination in dose and time administration as an antipyretic.
Collapse
|